GE HealthCare Reports $5.007 Billion Revenue in Q2 2025, Up 3.5% Year-Over-Year

GE HealthCare Technologies Inc. reported a total revenue of $5.007 billion for the second quarter of 2025, marking an increase of 3.5% from $4.839 billion in the same period of 2024. The company's net income attributable to GE HealthCare rose to $486 million, up from $428 million year-over-year, resulting in diluted earnings per share of $1.06, compared to $0.93 in the prior year. For the first half of 2025, total revenues reached $9.784 billion, a 3.1% increase from $9.489 billion in the first half of 2024, while net income attributable to GE HealthCare increased to $1.049 billion from $802 million.

The company experienced notable changes in its operational metrics, with product sales increasing to $3.263 billion from $3.207 billion and service sales rising to $1.743 billion from $1.632 billion in the second quarter. The gross profit for the quarter was $1.985 billion, slightly down from $2.002 billion in the previous year, while total operating expenses decreased to $1.331 billion from $1.395 billion. The reduction in operating expenses contributed to an operating income of $654 million, compared to $608 million in the prior year.

Strategically, GE HealthCare completed the acquisition of Nihon Medi-Physics Co., Ltd. on March 31, 2025, for $271 million, enhancing its pharmaceutical diagnostics segment. This acquisition is expected to bolster the company's presence in the Japanese market, particularly in radiopharmaceuticals. Additionally, the company acquired MIM Software Inc. in April 2024, further expanding its capabilities in medical imaging analysis and artificial intelligence solutions. The company also initiated a share repurchase program, authorizing up to $1 billion in stock buybacks, with $100 million spent in the second quarter.

Operationally, GE HealthCare reported a total employee headcount of 48,000 as of June 30, 2025, reflecting a slight increase from the previous year. The company also noted a significant rise in its cash and cash equivalents, which totaled $3.763 billion, up from $2.889 billion at the end of 2024. The company’s inventory levels increased to $2.283 billion from $1.939 billion, indicating a strategic buildup in preparation for anticipated demand.

Looking ahead, GE HealthCare anticipates continued revenue growth driven by its strategic investments in cloud computing, artificial intelligence, and software offerings. The company remains cautious about macroeconomic conditions, including geopolitical tensions and supply chain challenges, which could impact its operations. The management expressed confidence in its ability to navigate these challenges while focusing on innovation and expanding its market share in the healthcare technology sector.